An interventional study of Cognitive Behavioral Therapy and Exercise in Diabetes Mellitus, Type 2, Depressive Symptoms and Depression, sponsored by University of Michigan. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by University of Michigan · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Diabetes Mellitus, Type 2 by University of Michigan — 5 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of Michigan.
Among the 38 studies in Diabetes Mellitus, Type 2 by University of Michigan, this one is the 31st largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2025, is one of 31 with no phase, and was the 37th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →5 of the 38 studies in Diabetes Mellitus, Type 2 by University of Michigan are open now, in 2 countries. Recruiting first, the newest first:
University of Michigan · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18–80
University of Michigan · Sites in United States
Ages 14–18 · Healthy volunteers
University of Michigan · Sites in United States
Ages 30–85
University of Michigan · Sites in Guatemala
Ages 18+
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 19 is below the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 48 across the 36 interventional studies, 133 across the 2 observational. Of the 31 that completed or were terminated, 10 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Michigan is the lead sponsor of 1,509 studies on the registry; 194 are open to participants now.
Of its 170 completed or terminated interventional studies of FDA-regulated products, 134 (79%) have results posted.
2 of the studies in Diabetes Mellitus, Type 2 by University of Michigan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06007404University of MichiganUnderstanding Metabolism and Inflammation Risks for Diabetes in Adolescents | 2026-12 |
| NCT04442451University of MichiganMechanisms of Fatigability With Diabetes | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 38 studies in Diabetes Mellitus, Type 2 by University of Michigan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Michigan Men's Diabetes Project III: Mind \& Motion is an 7-month pilot randomized clinical trial. The investigators are looking to recruit 80 Black men with type 2 diabetes (T2D) (need to have diagnosis for at least one year) that are over the age of 18. Participants also must be under the care of a physician for their diabetes, self report an Hemoglobin A1c (A1C) of 7.0% or more in the last year, be willing to participate in study events (weekly physical activity, exercise and Cognitive Behavioral Therapy (CBT) sessions, group discussion sessions, and in-person health assessments), have reliable internet access (steady internet connection or unlimited data) that will allow them to use a tablet/phone/computer to complete study related tasks, live in the Wayne or Washtenaw County, and have reliable transportation to in-person events. All participants will receive 8 hours/sessions of cognitive behavioral therapy. Participants randomized to the intervention arm will also receive 8 sessions of guided exercise at the same time. Following that they will also receive 8 group discussion sessions that will serve as on-going support. All sessions will be help via Zoom. Additionally, all participants will participate in The 4 health assessments will take place at baseline, 10 weeks, 18 weeks, and 30 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Per American College of Sports Medicine (ACSM) guidelines, medical exclusion criteria will also include currently experiencing:
As part of the screening process, the investigators will ask the participant to self-report on these conditions. Participants who are currently receiving psychotherapy services for the treatment of depression from a mental health provider will be excluded. Participants who are currently receiving only medication management from a psychiatrist will be included.
If you are interested in the study, please complete our screening survey: https://redcapproduction.umms.med.umich.edu/surveys/?s=JNPPEDANX7KLPPF9. Thank you so much!
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to the intervention group will receive 8 one hour virtual sessions of individual cognitive behavioral therapy (CBT) that will take place via U-M Zoom, which is a HIPAA compliant virtual conferencing platform. Participants in this group will also receive 8 one hour virtual sessions of individual exercise. Participants in this group will also receive 8 one hour virtual group discussion sessions that will serve as on-going support. This group (4-8 participants) discussion will be facilitated by one CBT Interventionist and one Exercise Interventionist. These sessions will take place following the individual sessions of CBT and Exercise.
Behavioral: Cognitive Behavioral Therapy · Behavioral: Exercise · Behavioral: Group Discussions - Ongoing Support
Participants randomized to the control group will receive enhanced usual care (EUC). The EUC group will receive 8 sessions of standard Cognitive Behavioral Therapy.
Behavioral: Cognitive Behavioral Therapy
Cognitive behavioral therapy focuses on the unique needs of men. A culturally adapted CBT program will be administered to participants as it has demonstrated increased effectiveness for marginalized populations. Cognitive Behavioral Therapy (CBT) aligns well with these cultural needs due to its individualized approach, non-judgmental stance, collaborative nature, and emphasis on empowerment through skills building.
Research demonstrates a preference for physical activity interventions among men with chronic illnesses, while highlighting limited access to fitness facilities in low-income urban areas as a barrier to participation. Online physical activity interventions have shown efficacy and cost-effectiveness in improving health behaviors, with virtual exercise programs for low-income African American populations demonstrating significant reductions in depressive symptoms. Therefore participants will receive exercise to help improve their diabetes self-management behaviors and depressive symptoms.
Participants will join group discussions that will serve as on-going support. The small group component is designed to foster self-efficacy, autonomous motivation, and enjoyment by integrating skills building, personal values, spirituality, and goal setting. This approach has shown positive outcomes in previous pilot studies with African American men, serving as a source of vicarious learning and social support.
Change in A1C
Anthropometric/clinical data
Time frame: Screening, Baseline, 10 weeks, 18 weeks, 30 weeks
Change in General Quality of Life (12-Item Short Form Survey (SF-12))
Survey Data - 12 questions covering physical and mental health domains - Scores above 50 indicate a better-than-average health-related quality of life, while scores below 50 suggest below-average health.
Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks
Change in Diabetes-Related Distress (The Type 2 Diabetes Distress Assessment System)
Survey Data - The assessment system has two components: The Core Distress Scale and The Sources Scale. The CORE DISTRESS SCORE is simply the average of the 8 items of the CORE SCALE, with each item rated on a 1 to 5 scale: Mean score \< 2.0 indicate little or no distress, Mean score between 2.0 and 2.9 indicate moderate distress, Mean score \> 3.0 indicate high distress. The Sources scale aims to find the sources of the distress, whether CORE DISTRESS is high or low, it is helpful to identify those aspects of living with diabetes that are contributing to the individual's diabetes distress.
Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks
Change in Diabetes Quality of Life (Diabetes Quality of Life Instrument)
Survey Data - Survey answers range for each section of the survey asking about satisfaction, worry, and impact of diabetes. The DQoL measure consists of 46 items ranked on a 5-point Likert scale. Individual domain and DQoL total scores range from 0 (lowest possible QoL) to 100 (highest possible QoL).
Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks
Change in Diabetes Self-Efficacy (Perceived Diabetes Self-Management Scale)
Survey Data - The scale is an 8-item scale that uses a 5-point Likert scale to measure self-efficacy in diabetes management. The scale ranges from 8 to 40 points, with higher scores indicating greater self-efficacy.
Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks
Change in Masculinity Ideology (The Conformity to Masculine Norms Inventory-30)
Survey Data - The CMNI-30's subscales are scored by adding up the scores of each item. It is a 30-item scale that measures how much a person conforms to masculine norms in US society. The items are rated on a six-point Likert scale, ranging from 0 (strongly disagree) to 5 (strongly agree), with nine items reverse-coded.
Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks
Change in BMI
Anthropometric/clinical data
Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks
Chance in Estimated Abdominal Subcutaneous and Visceral Fat Stores
Anthropometric/clinical data
Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks
Change in Diabetes Social Support (Duke/UNC Functional Social Support)
Survey Data - Responses are scaled on a 1-5 scale and tallied to create a total score with higher values indicating greater social support.
Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks
Sociodemographic characteristics
Survey Data
Time frame: Baseline
Healthcare utilization
Survey Data
Time frame: Baseline
Comorbidities
Survey Data
Time frame: Baseline
Change in Medication Adherence (Adherence to Refills and Medicines Scale for Diabetes)
Survey Data - The scale a 14-question survey that measures self-reported medication adherence. The ARMS-D is designed to be brief and easy to use, and can help identify reasons for non-adherence. Each item on the scale is rated on a four-point Likert scale, with 1 being "none of the time" and 4 being "all of the time". The items are then summed to create a score that ranges from 11 to 44, with higher scores indicating better adherence.
Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks
Change in Aerobic Capacity (6 minute walk test)
Anthropometric/clinical data
Time frame: Baseline, 10 weeks, 30 weeks
Change in Working Alliance between Counselor & Participant (Working Alliance Inventory - Short Revised)
Survey Data - The Scale is 12 questions, Each item is scored from 1-7, minimum=1 to maximum=7, ranging from Never to Always. Higher scores reflect a more positive rating of working alliance.
Time frame: Up to 8 weeks
Change in Metabolic Control (continuous blood glucose levels)
Anthropometric/clinical data
Time frame: Up to 18 weeks
Change in Depression Symptoms (Patient Health Questionnaire 9)
Survey Data - Answer Options rang from Not at all = 0, Several days = 1, More than half the days = 2, Nearly every day = 3. Scores can range from 1 - 27, the higher the score, the more severe the depression.
Time frame: Screening and throughout study completion, up to 30 weeks.
Change in Blood Pressure (systolic and diastolic)
Anthropometric/clinical data
Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks
Change in Physical Activity Regimen
Exercise Log Data
Time frame: Up to 18 weeks
Change in Heart Rate
Anthropometric/clinical data
Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks
Ran from Jan 2025 to primary completion in Aug 2026, 19 months.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 19 months is close to that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Sep 2026 → Aug 2026 and completion Sep 2026 → Aug 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.